• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Vigene Biosciences Expands Montgomery County, Maryland, Operations and R&D Facilities

Vigene Biosciences, a global leader in gene therapy development, plans to expand into a new facility in Montgomery County, Maryland. The company will retain its current 125 employees and add up to 245 new jobs by the end of 2025.

In addition to its existing headquarters, R&D and manufacturing locations in Rockville, the company will lease 52,000 square feet of manufacturing space at 14200 Shady Grove Road, bringing the total lab and manufacturing space of the company to 110,000 square feet.

“Vigene serves over 4,000 clients worldwide, including our recently announced collaboration with Gaithersburg’s Altimmune to manufacture its single-dose intranasal vaccine candidate for COVID-19,” said Dr. Zairen Sun, Vigene’s president and CEO. “This new facility will allow us to support our customers as they move beyond clinical development into commercial scale manufacturing.”

To assist with project costs related to the expansion, the Maryland Department of Commerce has approved a $1,225,000 conditional loan contingent on job creation and capital investment. In addition, the state has approved a $100,000 Partnership for Workforce Quality training grant, and the company is eligible for several tax credits, including the Job Creation Tax Credit and More Jobs for Marylanders. Montgomery County has approved a $125,000 Economic Development Fund conditional grant contingent on job creation and capital investment.

“Vigene is at the forefront of developing products for gene and cellular therapy for people around the world battling cancer and other life-threatening disorders, and we are very excited that they are continuing to do that important work right here in Maryland,” said Maryland Commerce Secretary Kelly M. Schulz. “Together with our partners in Montgomery County, we look forward to working with Vigene to ensure they continue to grow and thrive here in our state.”

Founded in 2012, Vigene Biosciences’ mission is to make gene therapy affordable for patients with cancer and serious genetic disorders. The company develops, manufactures, and distributes state-of-the-art adeno-associated viruses (AAV), lentivirus, retrovirus, adenovirus, and plasmid viral vectors for gene delivery.

“It was just a year ago that we cut the ribbon at Vigene’s new custom-built headquarters and already the growing demand for its gene and cellular therapy products requires additional physical expansion,” said Benjamin H. Wu, president and CEO of Montgomery County Economic Development Corporation. “Vigene’s growth as a global innovation leader has been fueled by its local collaborations and access to a robust talent pipeline.”

In 2016, Vigene acquired Omnia Biologics with its significant clinical manufacturing experience to respond to growing product demand as gene therapy candidates progressed to clinical trials. The company’s global clientele includes pharmaceutical and biotech companies, governmental agencies, non-profit organizations, and academic institutions.

Exclusive Research